Pierre Broqua
Inventiva (France) · 88 works · 3,103 citations · h-index 23
Top works
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats
- GnRH Antagonists: A New Generation of Long Acting Analogues Incorporatingp-Ureido-phenylalanines at Positions 5 and 6
- Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures
- Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix
- Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism
- Evidence That the Inhibition of Luteinizing Hormone Secretion Exerted by Central Administration of Neuropeptide Y (NPY) in the Rat Is Predominantly Mediated by the NPY-Y5 Receptor Subtype1
- Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats
- Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach
- The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- Chronic Blockade of the Melanocortin 4 Receptor Subtype Leads to Obesity Independently of Neuropeptide Y Action, with No Adverse Effects on the Gonadotropic and Somatotropic Axes**This work was supported by grants from the Swiss National Research Science Foundation (31–39729-93, 31–55732-98, and 32–04912 3–97) and in part by Ferring Pharmaceuticals Ltd. Research Laboratories.
- Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
- Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist
- A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study
- Announcement
- Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
- Antinociceptive effects of neuropeptide Y and related peptides in mice
- Stimulation of the Gonadotropic Axis by the Neuropeptide Y Receptor Y1 Antagonist/ Y4 Agonist 1229U91 in the Male Rat